Predicting oxidation sites with order of occurrence among multiple sites for CYP4A-mediated reactions

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 4, 2011, Pages 351-363

  Yamaura, Yoshiyuki ^a,b   Yoshinari, Kouichi ^a   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Discovery Technology   (Finland)

Author keywords

CYP4A11; Cytochrome P450; Drug metabolism prediction; Fatty acid hydroxylation; In silico method; Regioselectivity; Template and scoring system

Indexed keywords

CYTOCHROME P450 4A;

ARTICLE; ATOMIC PARTICLE; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SUBSTRATE; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; OXIDATION KINETICS; PREDICTION; PROCESS DEVELOPMENT; SCORING SYSTEM; STRUCTURE ANALYSIS;

EID: 80052603590     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-004     Document Type: Article

References (65)

1. Kawashima, H., Kusunose, E., Kikuta, Y., Kinoshita, H., Tanaka, S., Yamamoto, S., Kishimoto, T. and Kusunose, M.: Purification and cDNA cloning of human liver CYP4A fatty acid omegahydroxylase. J. Biochem., 116: 74-80 (1994).
2. Alterman, M. A., Chaurasia, C. S., Lu, P., Hardwick, J. P. and Hanzlik, R. P.: Fatty acid discrimination and omega-hydroxylation by cytochrome P450 4A1 and a cytochrome P4504A1/NADPHP450 reductase fusion protein. Arch. Biochem. Biophys., 320: 289-296 (1995).
3. de Visser, S. P., Kumar, D., Cohen, S., Shacham, R. and Shaik, S.: A predictive pattern of computed barriers for C-h hydroxylation by compound I of cytochrome p450. J. Am. Chem. Soc., 126: 8362-8363 (2004).
4. Palmer, C. N., Richardson, T. H., Griffin, K. J., Hsu, M. H., Muerhoff, A. S., Clark, J. E. and Johnson, E. F.: Characterization of a cDNA encoding a human kidney, cytochrome P-450 4A fattyacid omega-hydroxylase and the cognate enzyme expressed in Escherichia coli. Biochim. Biophys. Acta, 1172: 161-166 (1993).
5. Fer, M., Corcos, L., Dreano, Y., Plee-Gautier, E., Salaun, J. P., Berthou, F. and Amet, Y.: Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J. Lipid Res., 49: 2379-2389 (2008).
6. Okita, R. T. and Okita, J. R.: Cytochrome P450 4A fatty acid omega hydroxylases. Curr. Drug Metab., 2: 265-281 (2001).
7. Mukoyoshi, M., Nishimura, S., Hoshide, S., Umeda, S., Kanou, M., Taniguchi, K. and Muroga, H.: In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica, 38: 496-510 (2008).
8. Adas, F., Salaun, J. P., Berthou, F., Picart, D., Simon, B. and Amet, Y.: Requirement for omega and (omega;-1)-hydroxylations of fatty acids by human cytochromes P450 2E1 and 4A11. J. Lipid Res., 40: 1990-1997 (1999).
9. Dhar, M., Sepkovic, D. W., Hirani, V., Magnusson, R. P. and Lasker, J. M.: Omega oxidation of 3-hydroxy fatty acids by the human CYP4F gene subfamily enzyme CYP4F11. J. Lipid Res., 49: 612-624 (2008).
10. Bambal, R. B. and Hanzlik, R. P.: Effects of steric bulk and conformational rigidity on fatty acid omega hydroxylation by a cytochrome P450 4A1 fusion protein. Arch. Biochem. Biophys., 334: 59-66 (1996).
11. Hoch, U., Zhang, Z., Kroetz, D. L. and Ortiz de Montellano, P. R.: Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omegahydroxylases. Arch. Biochem. Biophys., 373: 63-71 (2000).
12. Marill, J., Cresteil, T., Lanotte, M. and Chabot, G. G.: Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol. Pharmacol., 58: 1341-1348 (2000).
13. Marill, J., Capron, C. C., Idres, N. and Chabot, G. G.: Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cisretinoic acids. Biochem. Pharmacol., 63: 933-943 (2002).
14. Komen, J. C. and Wanders, R. J.: Identification of the cytochrome P450 enzymes responsible for the omega-hydroxylation of phytanic acid. FEBS Lett., 580: 3794-3798 (2006).
15. Le Quéré, V., Plee-Gautier, E., Potin, P., Madec, S. and Salaun, J. P.: Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. J. Lipid Res., 45: 1446-1458 (2004).
16. Cali, J. J., Ma, D., Sobol, M., Simpson, D. J., Frackman, S., Good, T. D., Daily, W. J. and Liu, D.: Luminogenic cytochrome P450 assays. Expert Opin. Drug Metab. Toxicol., 2: 629-645 (2006).
17. Promega Applications: http://www.promega.com/enotes/ applications/ap0092.html.
18. Oliw, E. H., Stark, K. and Bylund, J.: Oxidation of prostaglandin H(2) and prostaglandin H(2) analogues by human cytochromes P450: analysis of omega-side chain hydroxy metabolites and four stereoisomers of 5-hydroxyprostaglandin I(1) by mass spectrometry. Biochem. Pharmacol., 62: 407-415 (2001).
19. DeBarber, A. E., Bleyle, L. A., Roullet, J. B. and Koop, D. R.: Omega-hydroxylation of farnesol by mammalian cytochromes p450. Biochim. Biophys. Acta, 1682: 18-27 (2004).
20. Bambal, R. B. and Hanzlik, R. P.: Active site structure and substrate specificity of cytochrome P450 4A1: steric control of ligand approach perpendicular to heme plane. Biochem. Biophys. Res. Commun., 219: 445-449 (1996).
21. Alterman, M. A., Chaurasia, C. S., Lu, P. and Hanzlik, R. P.: Heteroatom substitution shifts regioselectivity of lauric acid metabolism from omega-hydroxylation to (omega-1)-oxidation. Biochem. Biophys. Res. Commun., 214: 1089-1094 (1995).
22. He, X., Cryle, M. J., De Voss, J. J. and de Montellano, P. R.: Calibration of the channel that determines the omega-hydroxylation regiospecificity of cytochrome P4504A1: catalytic oxidation of 12- HALODOdecanoic acids. J. Biol. Chem., 280: 22697-22705 (2005).
23. Cowart, L. A., Wei, S., Hsu, M. H., Johnson, E. F., Krishna, M. U., Falck, J. R. and Capdevila, J. H.: The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity peroxisome proliferator-activated receptor ligands. J. Biol. Chem., 277: 35105-35112 (2002).
24. Mathews, J. M., deCosta, K. and Thomas, B. F.: Lauramide diethanolamine absorption, metabolism, and disposition in rats and mice after oral, intravenous, and dermal administration. Drug Metab. Dispos., 24: 702-710 (1996).
25. Merdink, J., Decosta, K., Mathews, J. M., Jones, C. B., Okita, J. R. and Okita, R. T.: Hydroxylation of lauramide diethanolamine by liver microsomes. Drug Metab. Dispos., 24: 180-186 (1996).
26. Nakashima, A., Kawashita, H., Masuda, N., Saxer, C., Niina, M., Nagae, Y. and Iwasaki, K.: Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica, 35: 589-602 (2005).
27. Sontag, T. J. and Parker, R. S.: Cytochrome P450 omegahydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J. Biol. Chem., 277: 25290-25296 (2002).
28. Fukazawa, T., Yajima, K. and Miyamoto, Y.: Evaluation of drugdrug interaction potential of beraprost sodium mediated by P450 in vitro. Yakugaku Zasshi, 128: 1459-1465 (2008).
29. Lee, A. J., Cai, M. X., Thomas, P. E., Conney, A. H. and Zhu, B. T.: Characterization of the oxidative metabolites of 17betaestradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology, 144: 3382-3398 (2003).
30. Wang, M. Z., Saulter, J. Y., Usuki, E., Cheung, Y. L., Hall, M., Bridges, A. S., Loewen, G., Parkinson, O. T., Stephens, C. E., Allen, J. L., Zeldin, D. C., Boykin, D. W., Tidwell, R. R., Parkinson, A., Paine, M. F. and Hall, J. E.: CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4- amidinophenyl)furan-bis-O-methylamidoxime]. Drug Metab. Dispos., 34: 1985-1994 (2006).
31. Kamada, T., Chow, T., Hiroi, T., Imaoka, S., Morimoto, K., Ohde, H. and Funae, Y.: Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes. Drug Metab. Pharmacokinet., 17: 199-206 (2002).
32. Akutsu, T., Kobayashi, K., Sakurada, K., Ikegaya, H., Furihata, T. and Chiba, K.: Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab. Dispos., 35: 72-78 (2007).
33. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T. and Kurihara, A.: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos., 38: 92-99 (2010).
34. Ghosal, A., Chowdhury, S. K., Gupta, S., Yuan, Y., Iannucci, R., Zhang, H., Zbaida, S., Patrick, J. E. and Alton, K. B.: Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 351125, a CCR5 antagonist. Xenobiotica, 35: 405-417 (2005).
35. McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K. and Rettie, A. E.: CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 75: 1337-1346 (2009).
36. Asano, T., Kushida, H., Sadakane, C., Ishihara, K., Wakui, Y., Yanagisawa, T., Kimura, M., Kamei, H. and Yoshida, T.: Metabolism of ipecac alkaloids cephaeline and emetine by humanhepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol. Pharm. Bull., 24: 678-682 (2001).
37. Shiraga, T., Kaneko, H., Iwasaki, K., Tozuka, Z., Suzuki, A. and Hata, T.: Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica, 29: 217-229 (1999).
38. Gorman, G. S., Coward, L., Kerstner-Wood, C., Cork, L., Kapetanovic, I. M., Brouillette, W. J. and Muccio, D. D.: In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab. Dispos., 35: 1157-1164 (2007).
39. Rosenquist, T. A., Einolf, H. J., Dickman, K. G., Wang, L., Smith, A. and Grollman, A. P.: Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos., 38: 761-768 (2010).
40. Matsumoto, S. and Yamazoe, Y.: Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br. J. Clin. Pharmacol., 51: 133-142 (2001).
41. Toselli, F., Matthias, A., Bone, K. M., Gillam, E. M. and Lehmann, R. P.: Metabolism of the major Echinacea alkylamide N-isobutyldodeca-2E,4E,8Z,10Z-tetraenamide by human recombinant cytochrome P450 enzymes and human liver microsomes. Phytother. Res., 24: 1195-1201 (2010).
42. Hiratsuka, M., Hinai, Y., Sasaki, T., Konno, Y., Imagawa, K., Ishikawa, M. and Mizugaki, M.: Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab. Dispos., 35: 1730-1732 (2007).
43. Fujimaki, Y., Arai, N., Nakazawa, T. and Fujimaki, M.: Nefiracetam metabolism by human liver microsomes: role of cytochrome P450 3A4 and cytochrome P450 1A2 in 5- hydroxynefiracetam formation. J. Pharm. Pharmacol., 53: 795-804 (2001).
44. Ma, X., Idle, J. R., Krausz, K. W. and Gonzalez, F. J.: Metabolism of melatonin by human cytochromes p450. Drug Metab. Dispos., 33: 489-494 (2005).
45. Ramírez, J., Innocenti, F., Schuetz, E. G., Flockhart, D. A., Relling, M. V., Santucci, R. and Ratain, M. J.: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab. Dispos., 32: 930-936 (2004).
46. Wienkers, L. C. and Wynalda, M. A.: Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab. Dispos., 30: 1372-1377 (2002).
47. Huang, Y., Okochi, H., May, B. C., Legname, G., Prusiner, S. B., Benet, L. Z., Guglielmo, B. J. and Lin, E. T.: Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab. Dispos., 34: 1136-1144 (2006).
48. Yamamoto, T., Hagima, N., Nakamura, M., Kohno, Y., Nagata, K. and Yamazoe, Y.: Differences in cytochrome P450 forms involved in the metabolism of N,N-dipropyl-2-[4-methoxy-3-(2- phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100), a novel sigma ligand, in human liver and intestine. Drug Metab. Dispos., 31: 60-66 (2003).
49. Giri, S., Krausz, K. W., Idle, J. R. and Gonzalez, F. J.: The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochem. Pharmacol., 73: 561-573 (2007).
50. Madan, A., Fisher, A., Jin, L., Chapman, D. and Bozigian, H. P.: In vitro metabolism of indiplon and an assessment of its drug interaction potential. Xenobiotica, 37: 736-752 (2007).
51. Piver, B., Fer, M., Vitrac, X., Merillon, J. M., Dreano, Y., Berthou, F. and Lucas, D.: Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem. Pharmacol., 68: 773-782 (2004).
52. Obach, R. S., Margolis, J. M. and Logman, M. J.: In vitro metabolism of CP-122,721 -(2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor. Drug Metab. Pharmacokinet., 22: 336-349 (2007).
53. Rochat, B., Zoete, V., Grosdidier, A., von Grunigen, S., Marull, M. and Michielin, O.: In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm. Drug Dispos., 29: 103-118 (2008).
54. Nguyen, X., Wang, M. H., Reddy, K. M., Falck, J. R. and Schwartzman, M. L.: Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors. Am. J. Physiol., 276: R1691-R1700 (1999).
55. Wang, M. H., Brand-Schieber, E., Zand, B. A., Nguyen, X., Falck, J. R., Balu, N. and Schwartzman, M. L.: Cytochrome P450- derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J. Pharmacol. Exp. Ther., 284: 966-973 (1998).
56. Baer, B. R., Rettie, A. E. and Henne, K. R.: Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem. Res. Toxicol., 18: 855-864 (2005).
57. Casabar, R. C., Wallace, A. D., Hodgson, E. and Rose, R. L.: Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4. Drug Metab. Dispos., 34: 1779-1785 (2006).
58. Lasker, J. M., Chen, W. B., Wolf, I., Bloswick, B. P., Wilson, P. D. and Powell, P. K.: Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J. Biol. Chem., 275: 4118-4126 (2000).
59. Kehl, F., Cambj-Sapunar, L., Maier, K. G., Miyata, N., Kametani, S., Okamoto, H., Hudetz, A. G., Schulte, M. L., Zagorac, D., Harder, D. R. and Roman, R. J.: 20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat. Am. J. Physiol. Heart Circ. Physiol., 282: H1556-H1565 (2002).
60. Nakamura, T., Sato, M., Kakinuma, H., Miyata, N., Taniguchi, K., Bando, K., Koda, A. and Kameo, K.: Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14- eicosatetraenoic acid synthase inhibitors. J. Med. Chem., 46: 5416-5427 (2003).
61. Dierks, E. A., Zhang, Z., Johnson, E. F. and de Montellano, P. R.: The catalytic site of cytochrome P4504A11 (CYP4A11) and its L131F mutant. J. Biol. Chem., 273: 23055-23061 (1998).
62. Miyata, N., Seki, T., Tanaka, Y., Omura, T., Taniguchi, K., Doi, M., Bandou, K., Kametani, S., Sato, M., Okuyama, S., Cambj-Sapunar, L., Harder, D. R. and Roman, R. J.: Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011[N-(3-chloro-4-morpholin-4-yl) phenyl-Nö-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J. Pharmacol. Exp. Ther., 314: 77-85 (2005).
63. Wu, J. H., Hodgson, J. M., Clarke, M. W., Indrawan, A. P., Barden, A. E., Puddey, I. B. and Croft, K. D.: Inhibition of 20- hydroxyeicosatetraenoic acid synthesis using specific plant lignans: in vitro and human studies. Hypertension, 54: 1151-1158 (2009).
64. Hanzlik, R. P., Hogberg, K. and Judson, C. M.: Microsomal hydroxylation of specifically deuterated monosubstituted benzenes. Evidence for direct aromatic hydroxylation. Biochemistry, 23: 3048-3055 (1984).
65. Korzekwa, K. R., Swinney, D. C. and Trager, W. F.: Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation. Biochemistry, 28: 9019-9027 (1989).